[go: up one dir, main page]

SG10201803321TA - Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate - Google Patents

Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Info

Publication number
SG10201803321TA
SG10201803321TA SG10201803321TA SG10201803321TA SG10201803321TA SG 10201803321T A SG10201803321T A SG 10201803321TA SG 10201803321T A SG10201803321T A SG 10201803321TA SG 10201803321T A SG10201803321T A SG 10201803321TA SG 10201803321T A SG10201803321T A SG 10201803321TA
Authority
SG
Singapore
Prior art keywords
dimethylamino
propionate
dodecyl
ddaip
active enantiomer
Prior art date
Application number
SG10201803321TA
Inventor
Bassam B Damaj
Richard Martin
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of SG10201803321TA publication Critical patent/SG10201803321TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE 2R-dodecyl 2-(N,N dimethylamino)-propionate (R-DDAIP) provides an unexpectedly improved activity in facilitating transport of a pharmaceutically active compound across biological membranes and tissues, compared to SDDAIP of the same enantiomeric purity, or racemic DDAIP. Purified S-DDAIP is also provided. FIG. 1
SG10201803321TA 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate SG10201803321TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41899610P 2010-12-02 2010-12-02

Publications (1)

Publication Number Publication Date
SG10201803321TA true SG10201803321TA (en) 2018-06-28

Family

ID=46172526

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803321TA SG10201803321TA (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
SG2013035258A SG190199A1 (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013035258A SG190199A1 (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Country Status (20)

Country Link
US (1) US20130267562A1 (en)
EP (1) EP2646015B1 (en)
JP (1) JP6109075B2 (en)
KR (1) KR102004552B1 (en)
CN (1) CN103930105B (en)
AU (2) AU2011336692B2 (en)
BR (1) BR112013012799A8 (en)
CA (1) CA2817417C (en)
CL (1) CL2013001391A1 (en)
CR (1) CR20130324A (en)
ES (1) ES2801999T3 (en)
IL (1) IL226173A (en)
MX (1) MX2013005522A (en)
NZ (1) NZ609826A (en)
PH (1) PH12013501104A1 (en)
PL (1) PL2646015T3 (en)
RU (1) RU2679308C2 (en)
SG (2) SG10201803321TA (en)
WO (1) WO2012075107A2 (en)
ZA (1) ZA201304840B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028780A2 (en) * 2012-08-15 2014-02-20 Nexmed Holdings, Inc. Antifungal compounds and methods of use
US8900625B2 (en) 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
DE10033853A1 (en) * 2000-07-12 2002-01-31 Hexal Ag Transdermal therapeutic system with highly disperse silicon dioxide
EP1534235B1 (en) * 2002-06-25 2016-07-27 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
NZ542904A (en) * 2003-03-21 2009-04-30 Nexmed Holdings Inc Antifungal nail coat and method of use
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
MXPA06003316A (en) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.
US20050113274A1 (en) * 2003-11-22 2005-05-26 Nadir Buyuktimkin Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
JP5864543B2 (en) * 2010-05-04 2016-02-17 ネクスメッド ホールディングス，インコーポレイテッド Composition of small molecule therapeutic agent
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Also Published As

Publication number Publication date
CR20130324A (en) 2013-08-13
WO2012075107A3 (en) 2014-03-06
JP2014514243A (en) 2014-06-19
AU2011336692A1 (en) 2013-05-30
CL2013001391A1 (en) 2013-11-08
EP2646015A2 (en) 2013-10-09
EP2646015A4 (en) 2015-04-08
BR112013012799A8 (en) 2018-01-09
CN103930105A (en) 2014-07-16
SG190199A1 (en) 2013-06-28
CA2817417A1 (en) 2012-06-07
BR112013012799A2 (en) 2016-09-13
CN103930105B (en) 2019-11-01
CA2817417C (en) 2020-12-29
RU2679308C2 (en) 2019-02-07
JP6109075B2 (en) 2017-04-05
WO2012075107A2 (en) 2012-06-07
EP2646015B1 (en) 2020-04-22
RU2013119439A (en) 2015-01-10
ES2801999T3 (en) 2021-01-15
IL226173A0 (en) 2013-07-31
PH12013501104A1 (en) 2013-07-08
MX2013005522A (en) 2013-07-17
US20130267562A1 (en) 2013-10-10
KR20140023875A (en) 2014-02-27
ZA201304840B (en) 2014-04-30
KR102004552B1 (en) 2019-10-01
AU2011336692B2 (en) 2017-02-16
AU2017200314A1 (en) 2017-02-02
PL2646015T3 (en) 2020-11-30
IL226173A (en) 2016-10-31
NZ609826A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
USD800308S1 (en) Dental implant reusable bite registration post
USD659247S1 (en) Dental implant
GEP20135919B (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
USD683987S1 (en) Toilet tissue holder
ZA201004694B (en) Use of a fertilizer containing l-amino acid for improving root growth and growth of mycorrhiza
WO2007139933A3 (en) Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
EP2590655A4 (en) Compounds and methods for inhibiting phosphate transport
GEP20146100B (en) Novel phenylimidazole derivative as pde10a enzyme inhibitor
WO2012006474A3 (en) Compounds and methods for inhibiting phosphate transport
RS53521B1 (en) Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2008073138A3 (en) Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
MX2009006288A (en) New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-b enzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.
USD811211S1 (en) Catheter package
USD653879S1 (en) Table
PH12012501340A1 (en) Composition for improving brain function and method for improving brain function
MX2009012472A (en) Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis.
USD673458S1 (en) Package face
EP2316420A8 (en) Method to reduce pain
EP1902715A3 (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
SG10201803321TA (en) Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
USD666429S1 (en) Plant support
HRP20060079A2 (en) Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
IL209583A0 (en) 1 - (2-ethyl-butyl) - cyclohexanecarboxylic acid ester as an intermediate in the preparation of pharmaceutically active amides
WO2008155920A1 (en) Drug having effect of promoting hepatocyte growth
RU2008115908A (en) PHARMACEUTICAL COMPOSITION CONTAINING HYALURONIDASE AND LIPOSOMES FOR EXTERNAL USE